A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
01/2007
01/02/2007	US7156835 Method of applying composition to a surface
01/02/2007	CA2436275C Polymeric delivery formulations of leuprolide with improved efficacy
01/02/2007	CA2400226C Method for the improvement of islet signaling in diabetes mellitus and for its prevention
01/02/2007	CA2368615C Thiadiazolyl urea or thiourea derivatives for antiviral treatment
01/02/2007	CA2365495C Viral treatment
01/02/2007	CA2339991C Microemulsions as solid dosage forms for oral administration
01/02/2007	CA2295219C Integrin binding peptide and use thereof
01/02/2007	CA2237059C Targeted adenovirus vectors
01/02/2007	CA2218892C Diaromatic propynyl or dienyl compounds
01/02/2007	CA2197869C Therapeutic agent for cartilaginous diseases
01/02/2007	CA2174517C Receptor specific atrial natriuretic peptides
01/02/2007	CA2162468C Use of nona- and decapeptides in the preparation of a drug for the treatment of aids
12/2006
12/30/2006	CA2511200A1 Methods for increasing learning and memory in amyloid-beta-related neurodegenerative disorders by increasing uch-l1 activity and methods for identifying enhancers of uch-l1 activity
12/30/2006	CA2508691A1 Use of complement inhibitory proteins to treat spinal cord injury
12/29/2006	CA2551367A1 Multi-compartment delivery
12/29/2006	CA2549477A1 Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
12/28/2006	WO2006138729A2 Receptor antagonists for treatment of metastatic bone cancer
12/28/2006	WO2006138721A1 Anti-gfralpha3 antibodies
12/28/2006	WO2006138709A2 Lkktet and/or lkktnt peptide compositions and methods
12/28/2006	WO2006138708A1 Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized
12/28/2006	WO2006138707A1 Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage
12/28/2006	WO2006138668A2 Methods for treating dermatitis using mutant human il-4 compositions
12/28/2006	WO2006138558A2 Cytotoxic ribonuclease variants
12/28/2006	WO2006138468A2 Use of vegf for wound healing
12/28/2006	WO2006138466A2 Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
12/28/2006	WO2006138458A1 Cytotoxic ribonuclease variants
12/28/2006	WO2006138355A2 Effect of bri proteins on abeta production
12/28/2006	WO2006138343A2 Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
12/28/2006	WO2006138325A2 Fragment of neurosecretory protein vgf as a biomarker for alzheimer's disease
12/28/2006	WO2006138316A2 Methods for delivering molecules to the central nervous system
12/28/2006	WO2006138276A2 Improved antimicrobial peptides and uses thereof
12/28/2006	WO2006138238A2 Methods of protecting against apoptosis using lipopeptides
12/28/2006	WO2006138099A2 Bone morphogenetic protein formulations
12/28/2006	WO2006138098A1 Reinforced collagen scaffold
12/28/2006	WO2006138043A2 Method and compositions for the treatment of diabetes and related complications
12/28/2006	WO2006138038A1 Intralesional treatment of psoriasis
12/28/2006	WO2006138026A2 Stable pharmaceutical compositions including motilin-like peptides
12/28/2006	WO2006138023A1 Stable buffered, pharmaceutical compositions including motilin-like peptides
12/28/2006	WO2006137597A1 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances
12/28/2006	WO2006137595A1 Prophylactic/therapeutic agent for her2-expressing cancer
12/28/2006	WO2006137515A1 Therapeutic agent for cancer comprising polypeptide capable of inhibiting the function of synoviolin as active ingredient
12/28/2006	WO2006137514A1 Therapeutic agent for cancer comprising substance capable of inhibiting expression or function of synoviolin as active ingredient and screening method for the therapeutic agent for cancer
12/28/2006	WO2006137426A1 Prophylactic or therapeutic agent for corneal/conjunctival disease
12/28/2006	WO2006137398A1 Therapeutic agent for cancer
12/28/2006	WO2006137341A1 Agent for visualizing vitreous body
12/28/2006	WO2006137075A1 Compositions and methods for preventing or treating hiv infection
12/28/2006	WO2006137060A1 Immune disease medicament comprising a modulator of the binding between a heparin binding domain of thrombospondin-1 and a beta1 integrin
12/28/2006	WO2006136697A2 Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection
12/28/2006	WO2006136454A2 Use of inhibitors of n-methyl transferases for the therapy of parkinson's disease
12/28/2006	WO2006136161A2 Amylases for pharmaceutical use
12/28/2006	WO2006136160A2 Proteases for pharmaceutical use
12/28/2006	WO2006136159A2 Lipases for pharmaceutical use
12/28/2006	WO2006136116A1 Use of interferon-alpha in order to obtain a compound for the treatment of optical neuromyelitis
12/28/2006	WO2006136006A1 Lgi, lingo and p75ntr family members: novel modulators of neuronal growth
12/28/2006	WO2006135985A1 Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
12/28/2006	WO2006135943A1 Use of a proline-rich peptide derived from the hypothalamus for the manufacture of a medicament for the treatment and/or prophylaxis of cattle leucosis
12/28/2006	WO2006111720A3 Use
12/28/2006	WO2006099480A3 Stress proteins and peptides and methods of use thereof
12/28/2006	WO2006097536A3 Dimeric peptide agonists of the glp-1 receptor
12/28/2006	WO2006097462A3 Compositions and methods for treating inflammatory cns disorders
12/28/2006	WO2006091767A3 Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
12/28/2006	WO2006089954A3 Compounds for stabilizing factor vii polypeptide formulations
12/28/2006	WO2006076169A3 Treatment or prevention of genital viral infections with immunomodulator compounds
12/28/2006	WO2006072625A3 Anti-kir combination treatments and methods
12/28/2006	WO2006047357A3 Human ly6-big molecules and methods of use
12/28/2006	WO2006023452A3 Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
12/28/2006	WO2006013462A3 Growth factors nsg28, nsg30, and nsg32
12/28/2006	WO2006012492A8 Compositions and methods for viscosupplementation
12/28/2006	WO2006002437A3 Treatment of conditions involving demyelination
12/28/2006	WO2005098433A3 Diagnostic assays for alzheimer’s disease
12/28/2006	WO2005079525A3 A method for the production of transgenic proteins useful in the treatment of obesity and diabetes
12/28/2006	WO2005079271A3 Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
12/28/2006	WO2005074655A3 Materials and method for promotion of nerve regeneration
12/28/2006	WO2005058243A3 Methods for treating cancer using vascular endothelial cell growth inhibitor vegi-192a
12/28/2006	WO2005009337A3 Treating severe acute respiratory syndrome
12/28/2006	WO2004041067A3 Prevention and treatment of synucleinopathic disease
12/28/2006	WO2004020599A3 Hedgehog antagonists, methods and uses related thereto
12/28/2006	WO2003072714A3 Follistatin domain containing proteins
12/28/2006	US20060294614 Orphan receptors; drug screening; host cells
12/28/2006	US20060294612 Gpcr-like retinoic acid-induced gene 1 protein and nucleic acid
12/28/2006	US20060294605 Novel human dickkopf-related protein and nucleic acid molecules and uses therefor
12/28/2006	US20060294602 Diagnostic and therapeutic use of a rab family gtp-binding protein for neurodegenerative diseases
12/28/2006	US20060293512 Novel human uncoupling proteins and polynucleotides encoding the same
12/28/2006	US20060293507 Crystallization of IGF-1
12/28/2006	US20060293505 Crystal of a truncated protein construct containing a coagulation factor VIII C2 domain in the presence or absence of a bound ligand and methods of use thereof
12/28/2006	US20060293372 Beta-sheet mimetics and methods relating to the use thereof
12/28/2006	US20060293306 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons
12/28/2006	US20060293272 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
12/28/2006	US20060293271 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
12/28/2006	US20060293269 oligonucleotide with modified phosphorothioate linkage, sugar moiety, or nucleobase; disease or condition associated with expression of superoxide dismutase 1
12/28/2006	US20060293262 inhibiting HIV entry into CCR5-expressing cells; treatment and prevention of infectious diseases or disorders, e.g., HIV infection, AIDS, and AIDS-related diseases
12/28/2006	US20060293248 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
12/28/2006	US20060293247 Peptide derivatives; thyrotropin-releasing hormone-degrading; brain and spinal injuries, central nervous system disorders
12/28/2006	US20060293246 Methods of modulating beta cell function
12/28/2006	US20060293245 P21 derived peptides and uses thereof
12/28/2006	US20060293244 Anti-inflammatory compounds and uses thereof
12/28/2006	US20060293243 Stable, buffered, pharmaceutical compositions including motilin-like peptides
12/28/2006	US20060293242 Transporting of taxoid derivatives through the blood brain barrier
12/28/2006	US20060293241 Pharmaceutical composition comprising a factor VII polypeptide and epsilon-aminocaproic acid
12/28/2006	US20060293240 Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy

1 ... 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 ... 3163